Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GS-9820 · 1 trial · 1 indication
MTD will be assessed to determine the appropriate dosing regimens for use in future clinical trials of GS-9820 in subjects with lymphoid malignancies.
| Arm | Type | Description |
|---|---|---|
| GS-9820 | EXPERIMENTAL | Participants will be sequentially enrolled at progressively higher dose levels to receive GS-9820 administered twice a day. Escalation will proceed to the maximum tolerated dose (MTD), defined as the highest tested dose associated with a rate of dose-limiting toxicities (DLT) of \< 33% during the first 4 weeks of therapy. |
| Name | Type | Description |
|---|---|---|
| GS-9820 | DRUG | GS-9820 tablets containing 200 mg of GS-9820 administered orally |
Inclusion Criteria: * Previously treated recurrent B-cell iNHL, DLBCL, MCL, HL or CLL * Measurable lymphadenopathy * Requires therapy Exclusion Criteria: * Recent history of a major non-lymphoid malignancy * Evidence of ongoing infection * Concurrent participation in another therapeutic clinical ...
GS-9820 is an investigational small molecule being studied for the treatment of lymphoid malignancies, a group of blood cancers that affect the lymphatic system. It is currently in Phase 1 clinical development and has not been approved for any use.
GS-9820 is being developed by Gilead Sciences, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol GILD. The drug is currently in Phase 1 clinical development for lymphoid malignancies.
GS-9820 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 1b study evaluating the drug in subjects with lymphoid malignancies has been completed.
GS-9820 has been studied in one completed clinical trial, NCT01705847, a Phase 1b study evaluating the drug in subjects with lymphoid malignancies. The trial enrolled 39 participants in the Netherlands and was not randomized or blinded.
No alternative names for GS-9820 have been disclosed. The drug is identified by its code name GS-9820 and is being developed by Gilead Sciences for lymphoid malignancies.